All Proposals Approved at Teva’s Annual Shareholders Meeting
– Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that all proposals were approved at its Annual General Meeting of Shareholders held earlier today. These proposals included the appointment More...
Teva wins US court ruling on generic breast cancer drug
– Bristol-Myers Squibb’s Baraclude has $314 million in US annual sales. – – Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced that the U.S. Court of Appeals for the Federal More...
Teva Receives Sole Exclusivity for Generic Celebrex
– Teva Receives Favorable Court Decision Regarding Generic Celebrex® Capsules; Teva Should Receive Sole Exclusivity for Generic Celebrex Capsules. – – Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) More...
Teva, OncoGenex Prostate Cancer Therapy Misses Endpoint
– Teva CSO Dr. Michael Hayden: We are disappointed with these results. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ:OGXI) today announced results from More...
Takeda to sell Teva Parkinson’s treatment in Japan
– Teva and Takeda Agree to Commercialize Rasagiline for Parkinson’s Disease Treatment in Japan. – Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) and Takeda Pharmaceutical Company Limited (Takeda) More...
US Supreme Court denies Teva stay in Copaxone patent fight
– The US Supreme Court has in effect allowed generic versions of the MS drug from next month. – – Teva Pharmaceutical Industries Ltd. TEVATEVA (NYSE: ; TASE: ) has suffered a setback More...
Teva Settles Patent Litigation with Pfizer on arthritis treatment Celebrex
– Brand Celebrex has $2.2 billion in US sales in 2013, according to IMS data. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that its subsidiary Teva Pharmaceuticals USA, Inc. has More...
Teva Announces Approval Of Generic Breast Cancer, Osteoporosis Drug Evista Tablets In The US
– Teva has 180 days of marketing exclusivity for generic Evista, which had 2013 US sales of $824 million. Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announces the approval from the US Food and More...
Teva Launches The First And Only Orall Inhaler Medicine For Bipolar, Schizophrenia Treatment
– The first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. – – Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) launch More...
Teva and Active Biotech to Continue Laquinimod for Multiple Sclerosis Development Despite EMA
– Europe’s Committee for Medicinal Products for Human Use: The risk-benefit profile of laquinimod is not favorable at this time. – – Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) More...